A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma-Reference-Cited by-同舟云学术

A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma

Published:2017-06-13 Issue:10 Volume:66 Page:1359-1366
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Patel Sapna P.,Kim Dae Won,Bassett Roland L.,Cain Suzanne,Washington Edwina,Hwu Wen-Jen,Kim Kevin B.,Papadopoulos Nicholas E.,Homsi Jade,Hwu Patrick,Bedikian Agop Y.

Funder

Bristol-Myers Squibb

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-017-2030-y/fulltext.html

Reference20 articles.

1. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33(17):1889–1894. doi: 10.1200/JCO.2014.56.2736

2. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A, Investigators K (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521–2532. doi: 10.1056/NEJMoa1503093

3. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. doi: 10.1056/NEJMoa1003466

4. Bracci L, Schiavoni G, Sistigu A, Belardelli F (2014) Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 21(1):15–25. doi: 10.1038/cdd.2013.67

5. Middleton MR, Lee SM, Arance A, Wood M, Thatcher N, Margison GP (2000) O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer 88(3):469–473

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of solid tumors;Cochrane Database of Systematic Reviews;2024-01-16

2. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis;Cancers;2024-01-13

3. Effects of temozolomide on tumor mutation burden and microsatellite instability in melanoma cells;The Journal of Dermatology;2023-09-02

4. Pathology and Molecular Biology of Melanoma;Current Issues in Molecular Biology;2023-06-30

5. Combination of pembrolizumab plus temozolomide therapy in unresectable and advanced melanoma: a multicenter retrospective analysis in China;Annals of Translational Medicine;2021-11